LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets.

Hazeldine, Jon / Lord, Janet M

Frontiers in immunology

2021  Volume 12, Page(s) 680134

Abstract: ... phenotype and function of the neutrophil pool in COVID-19 patients of differing disease severities and ... a potential therapeutic target for the treatment of patients with severe COVID-19. ... currently approved for COVID-19, we conclude the review by discussing whether neutrophils represent ...

Abstract Whilst the majority of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of COVID-19, experience mild to moderate symptoms, approximately 20% develop severe respiratory complications that may progress to acute respiratory distress syndrome, pulmonary failure and death. To date, single cell and high-throughput systems based analyses of the peripheral and pulmonary immune responses to SARS-CoV-2 suggest that a hyperactive and dysregulated immune response underpins the development of severe disease, with a prominent role assigned to neutrophils. Characterised in part by robust generation of neutrophil extracellular traps (NETs), the presence of immature, immunosuppressive and activated neutrophil subsets in the circulation, and neutrophilic infiltrates in the lung, a granulocytic signature is emerging as a defining feature of severe COVID-19. Furthermore, an assessment of the number, maturity status and/or function of circulating neutrophils at the time of hospital admission has shown promise as a prognostic tool for the early identification of patients at risk of clinical deterioration. Here, by summarising the results of studies that have examined the peripheral and pulmonary immune response to SARS-CoV-2, we provide a comprehensive overview of the changes that occur in the composition, phenotype and function of the neutrophil pool in COVID-19 patients of differing disease severities and discuss potential mediators of SARS-CoV-2-induced neutrophil dysfunction. With few specific treatments currently approved for COVID-19, we conclude the review by discussing whether neutrophils represent a potential therapeutic target for the treatment of patients with severe COVID-19.
MeSH term(s) COVID-19/immunology ; Extracellular Traps/immunology ; Humans ; Neutrophils/immunology ; SARS-CoV-2/immunology
Language English
Publishing date 2021-06-02
Publishing country Switzerland
Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID 2606827-8
ISSN 1664-3224 ; 1664-3224
ISSN (online) 1664-3224
ISSN 1664-3224
DOI 10.3389/fimmu.2021.680134
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top